Eye contact is key to meaningful conversation, connection
Investigators at Dartmouth College have found that eye contact during a conversation makes the discussion more appealing to its participants.
Analyzing classifications of macula dystrophies
Carel B. Hoyng, MD, discusses his presentation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.
Hurricane Ida creates hurdles for ophthalmologists and patients
Amid a surging COVID-19 pandemic, ophthalmologists in the path of Hurricane Ida are now dealing with the storm's impact.
Maternal diabetes linked to high refractive error in offspring
A new study reveals that children of mothers with diabetes during pregnancy have an increased risk of eye problems.
Investigators report lab-grown brain cell clusters develop primitive "eyes"
Science fiction is quickly becoming science fact as a team of German scientists has developed a small, lab-grown brain cell cluster that developed fundamental eye structures.
AAO annual meeting participants required to provide proof of COVID-19 vaccination
The American Academy of Ophthalmology issued a guidance this week requiring all in-person attendees at its annual meeting Nov. 12-15 in New Orleans to show proof of COVID-19 vaccination.
ASRS provides health and safety update for annual meeting
The American Society of Retina Specialists is gearing up for its 39th annual scientific meeting Oct. 8-12 at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.
Study suggests gene therapy could prevent vision loss in patients with retinal disease or injury
Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.
Research suggests link between long COVID-19 and corneal nerve damage
A team of investigators used corneal confocal microscopy to identify corneal nerve damage in cases of long COVID-19.
Optogenetic gene therapy trial begins, first patient dosed
Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.
Laser imaging system may offer early detection, treatment for eye diseases that cause blindness
According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.
Outlook Therapeutics approaching FDA approval of bevacizumab-vikg for wet AMD treatment
The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.
Patient with retinitis pigmentosa achieves partial vision through gene therapy
An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.
Analysis of 24-month data from the PALADIN study
Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
A look at real-world trial data replication outcomes from IRIS Registry data
Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.
Linking patient imaging data to AAO IRIS Registry
Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.
Analyzing clinical results of dexamethasone implant effect on macular thickness
Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Targeting neurodegenerative diseases with risuteganib as treatment therapy
Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.
ARVO 2021: Stage set for ‘Revolutionary Eye and Vision Research’
Let the countdown begin for May as ‘month of ARVO’ and Annual Meeting
What keeps ophthalmologists up at night (Part III)
From patient care and treating glaucoma to the ongoing pandemic, ophthalmologists share the most pressing thoughts of concern leaving them awake at night.
Safety and efficacy of KPI-121 0.25% for DED treatment
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.
Analyzing an investigational ophthalmic solution for treating presbyopia-related symptoms
Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
Evaluating long-term safety of micro-bypass implant + phaco in PXG
Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.
Violet light-filtering IOLs: visual and non-visual benefits
Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.
Drug delivery vs drops: Controlling postop pain, inflammation in cataract patients
John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.
Single administration of intracameral bimatoprost implant: IOP lowering, safety
Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.
Integrating AI to manage DR in a primary care setting
Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.
AAO 2020: Comparing outcomes of xen gel stents in glaucoma practice
Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.
Novartis: Positive DME data for brolucizumab in KITE trial
Novartis has announced positive topline results from the phase 3 KITE study of brolucizumab 6 mg versus aflibercept for patients with diabetic macular edema.
FDA grants fourth ODD for treatment of PDE6B gene mutation-associated retinal diseases
The FDA has granted the fourth Orphan Drug Designation for a novel gene therapy product candidate (OCU400, Ocugen Inc.) in the treatment of PDE6B gene mutation-associated retinal diseases.
2 Clarke Drive Cranbury, NJ 08512